Ischemic heart disease is the most common cause of heart failure. For the treatment of heart failure, medical treatment, heart transplantation, and revascularization can be a therapeutic method (Challapalli S, Bonow RO, Gheorghiade M. Coron Artery Dis 9:659–674, 1998). Because of the ease of the procedure and good therapeutic performance, revascularization has been widely used in ischemic heart disease (Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG. J Am Coll Cardiol 22(4):1141–1154, 1993). However, revascularization has a substantial degree of risk associated with the procedure, especially in patients with severe heart failure, and heart function is recovered only in some of the patients who undergo revascularization (Schinkel AF, Poldermans D, Vanoverschelde JL, Elhendy A, Boersma E, Roelandt JR, et al. Am J Cardiol 93:14–17, 2004).
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Challapalli S, Bonow RO, Gheorghiade M. Medical management of heart failure secondary to coronary artery disease. Coron Artery Dis. 1998;9:659–74.PubMedGoogle Scholar
Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS) CASS Participating Investigators and Staff. J Am Coll Cardiol. 1993;22(4):1141–54.PubMedCrossRefGoogle Scholar
Schinkel AF, Poldermans D, Vanoverschelde JL, Elhendy A, Boersma E, Roelandt JR, et al. Incidence of recovery of contractile function following revascularization in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2004;93:14–7.PubMedCrossRefGoogle Scholar
Maes A, Flameng W, Nuyts J, Borgers M, Shivalkar B, Ausma J, et al. Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings. Circulation. 1994;90:735–45.PubMedCrossRefGoogle Scholar
Vanoverschelde JL, Melin JA. The pathophysiology of myocardial hibernation: current controversies and future directions. Prog Cardiovasc Dis. 2001;43:387–98.PubMedCrossRefGoogle Scholar
Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart. 2004;90(Suppl 5):v26–33.PubMedCrossRefGoogle Scholar
Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26:147–86.PubMedCrossRefGoogle Scholar
Bax JJ, Maddahi J, Poldermans D, Elhendy A, Cornel JH, Boersma E, et al. Sequential (201)Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after revascularization. J Nucl Med. 2002;43(6):795–802.PubMedGoogle Scholar
Samady H, Elefteriades JA, Abbott BG, Mattera JA, McPherson CA, Wackers FJ. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100:1298–304.PubMedCrossRefGoogle Scholar
Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999;33:750–8.PubMedCrossRefGoogle Scholar
Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation. 1993;87:1–20.PubMedCrossRefGoogle Scholar
Bonow RO, Dilsizian V. Thallium-201 and technetium-99 m-sestamibi for assessing viable myocardium. J Nucl Med. 1992;33:815–8.PubMedGoogle Scholar
Sciagrà R, Pellegri M, Pupi A, Bolognese L, Bisi G, Carnovale V, Santoro GM. Prognostic implications of Tc-99 m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2000;36:739–45.PubMedCrossRefGoogle Scholar
King LM, Opie LH. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. Cardiovasc Res. 1998;39:381–92.PubMedCrossRefGoogle Scholar
Gropler RJ. Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose. J Nucl Cardiol. 1994;1:S4–14.PubMedCrossRefGoogle Scholar
Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki LM, Mäki M, Ruotsalainen U, Härkönen R, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med. 1994;35:989–98.PubMedGoogle Scholar
Bax JJ, Patton JA, Poldermans D, Elhendy A, Sandler MP. 18-Fluorodeoxyglucose imaging with positron emission tomography and single photon emission computed tomography: cardiac applications. Semin Nucl Med. 2000;30:281–98.PubMedCrossRefGoogle Scholar
Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527–33.PubMedCrossRefGoogle Scholar
Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med. 1994;35:707–15.PubMedGoogle Scholar
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8.PubMedCrossRefGoogle Scholar